AbbVie blood cancer drug fast-tracked by FDA

SHARE AbbVie blood cancer drug fast-tracked by FDA

A possible blood cancer treatment developed by Abbvie Inc. and Bristol-Myers Squibb Co. has been picked by the Food and Drug Administration for fast-track review and possible approval.

The companies announced Monday the FDA’s designation of elotuzumab as a “breakthrough therapy.” The designation is intended to speed up development and review of drugs for serious or life-threatening conditions.

The therapy treats multiple myeloma, a progressive blood cancer that originates in the bone marrow. The companies said it is the second most common blood cancer and remains incurable. In 2014, about 24,050 new cases are expected to be diagnosed in the U.S. and more than 11,000 Americans will likely die from the disease, the companies said.

AbbVie Q1 tops estimates on strong Humira sales

AbbVie seeks OK for new hepatitis C drug

AbbVie to move 2,000 employees off North Chicago campus

The Latest
The gunfire erupted around 2:30 a.m. Saturday at a rental home in the Beverly Crest area, an upscale neighborhood, police said.
Dickinson, an amateur woodworker during the summertime, proved surprisingly successful as Patrick Kane’s center this week.
Dave Dempsey caught and released a lake trout while perch fishing with a hand-tied tinsel jig.
In Netflix doc, the longtime celeb opens up her diaries and speaks with candor about her difficult childhood, her sex tape and her roller-coaster marriages.